Tag: US-commercial-BCI-cohort

2 articles

Industry News

Merge Labs picks Butterfly's ultrasound-on-chip for its brain-computer interface build

Merge Labs, the US$252 million OpenAI-backed neural interface startup, has selected Butterfly Network (NYSE:BFLY) as its exclusive ultrasound-on-chip supplier under a multi-year Butterfly Embedded licensing deal announced 1 September 2026. The agreement covers Butterfly's Poseidon Family of Ultrasound-on-Chip for Merge's neural interface development, with upfront payments, milestones, hardware purchase commitments, technology access fees, and future royalties. Financial figures were not disclosed. Butterfly retains the right to license the same technology to other companies in the field. Ultrasound BCI now has a US-listed industrial supply chain.

Sep 1

Industry News

Paradromics wins FDA approval to connect its Connexus BCI to personal laptops, tablets and phones inside Connect-One

Paradromics announced on 26 August 2026 that the US Food and Drug Administration has issued an approval letter expanding the types of computing devices that may be used with its Connexus brain-computer interface inside the Connect-One Early Feasibility Study. Compatible personal, internet-connected devices (laptops, tablets, phones) can now be added into the study without a per-device FDA approval. Paradromics also identified a second patient for the feasibility study, and its first patient has progressed to closed-loop stage.

Aug 26